


IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/CA2004/000626	28.04.2004 28 April 2004	28.04.2003 28 April 2003

TITLE OF INVENTION: SARS VIRUS NUCLEOTIDE AND AMINO ACID SEQUENCES AND USES THEREOF

APPLICANT(S) FOR EO/DO/US: FRANK PLUMMER, et al.
U.S.S.N.: 10/555,073

CERTIFICATE OF MAILING	
I hereby certify that this correspondence, on the date shown below, is being deposited with the United States Postal Service with sufficient postage as Express Mail Label No. EV653005482 US in an envelope addressed to Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 .	
Date: Nov. <u>30</u> , 2006	 Tina-Michelle Pittsley

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir/Madam:

INFORMATION DISCLOSURE STATEMENT

In accordance with the provisions of 37 C.F.R. §1.56, 1.97, and 1.98, Applicants wish to bring to the Examiner's attention the following references, References C1-C8 cited in the attached Form PTO/SB/08B.

REMARKS

In accordance with the provisions of 37 C.F.R. §1.97, this statement is being filed:

- X (1) within three (3) months of the Filing Date or **before the mailing date of the First Office Action** on the merits; or
- (2) within three months of the mailing date of the PCT International Search Report; or
- (3) after the period defined in (1) but before the mailing date of a **Final Rejection or Notice of Allowance**, and the requisite Certification or fee under Rule 1.17(p), namely **\$180.00**, is included herein; or

IN THE UNITED STATES RECEIVING OFFICE

International Application Number	International Filing Date	International Earliest Priority Date
PCT/CA2004/000626	28.04.2004 28 April 2004	28.04.2003 28 April 2003

**TITLE OF INVENTION: SARS VIRUS NUCLEOTIDE AND AMINO ACID
SEQUENCES AND USES THEREOF**

APPLICANT(S) FOR EO/DO/US: FRANK PLUMMER, et al.
U.S.S.N.: 10/555,073

_____ (4) after the mailing date of a **Final Rejection** or **Notice of Allowance**
but before the payment of the **Issue Fee**, and the requisite
Certification, petition, and petition fee are included herein.

_____ A copy of the International Search Report is enclosed herewith.

It is respectfully requested that each of the documents shown on the attached
form(s) PTO/SB/08a be made of record in this application.

Copies of these documents (CHECK ONE):

 X are enclosed herewith; or

_____ have been cited in the parent application, and are thus not being resubmitted
herein.


_____ pursuant to 37 C.F.R. §1.98, copies of issued U.S. patents listed on the
attached form PTO/SB/08, if any, are no longer required and therefore are not
enclosed. These documents can be found in the U.S. PTO issued patents
database.

FEE AUTHORIZATION

The Commissioner is authorized to charge fee deficiencies or credit overpayments
associated with this submission to the NIXON PEABODY LLP Deposit Account No. 19-
2380.

Date: November 20 , 2006

Respectfully submitted,



Ronald I. Eisenstein (Reg. No. 30,628)
Leena H. Karttunen (L0207)
NIXON PEABODY LLP
100 Summer Street
Boston, MA 02110-2131
(617) 345-6054

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known		
			Application Number	10/555,073	
			I. A. Filing Date	28 April, 2004	
			First Named Inventor	Frank Plummer	
			Group Art Unit	To be assigned	
Examiner Name	To be assigned				
Sheet	1	of	1	Attorney Docket Number	030841-054132-US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
/B.P./	C1	Marra, Marco A. et al. The Genome Sequence of the SARS-Associated Coronavirus <i>Science</i> . (2003) 300 : 1399-404	
/B.P./	C2	Rota, Paul A. et al. Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome. <i>Science</i> . (2003) 300 : 1394-9	
/B.P./	C3	Anand, Kanchan et. al. Coronavirus Main Protocinase (3CLpro) Structure: Basis for Design of anti-SARS Drugs. <i>Science</i> . (2003) June 300 : 1763-7	
	C4	Genbank Database "SARS coronavirus, complete genome" XP002294214 Accession No: NC_004718 Didn't provide the document.	
	C5	Genbank Database "SARS coronavirus, complete genome" XP002294215 Accession No: NC_004718 Didn't provide the document.	
	C6	Genbank Database "SARS coronavirus, complete genome" XP002294216 Accession No: NC_004718 Didn't provide the document	
	C7	Genbank Database "SARS coronavirus Urbani" XP002294217 Accession No: AY278741 Didn't provide the document.	
	C8	Genbank Database "SARS coronavirus GUHK-W1" XP002294245 Accession No: AY278554 Didn't provide the document.	

Examiner Signature	/Bo Peng/	Date Considered	10/15/2010
--------------------	-----------	-----------------	------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.